Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.76 |
| ▸ | CNR1 | P21554 | 10/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205244 | 0.90 | CNR2 (0.63) | CNR2CNR1ALDH1A1ESR1CYP3A4 | |
| SCHEMBL1206461 | 0.87 | CNR2 (1.00) | CNR2CNR1ALDH1A1ESR1CYP3A4 | |
| SCHEMBL1206416 | 0.78 | CNR2 (0.68) | CNR2CNR1ALDH1A1ESR1CYP3A4 | |
| SCHEMBL11639123 | 0.76 | ESR1 (0.52) | CNR2CNR1ALDH1A1ESR1CYP3A4 | |
| SCHEMBL1206833 | 0.76 | CNR1 (1.00) | CNR2CNR1ALDH1A1ESR1CYP3A4 | |
| SCHEMBL28054006 | 0.74 | CNR2 (0.76) | CNR2CNR1ALDH1A1ESR1CYP3A4 | |
| SCHEMBL1205819 | 0.73 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL15516390 | 0.72 | CNR2 (1.00) | CNR2CNR1ALDH1A1 | |
| SCHEMBL1491149 | 0.71 | CNR2 (0.65) | CNR2CNR1ALDH1A1ESR1CYP3A4 | |
| SCHEMBL1205883 | 0.70 | CNR2 (0.65) | CNR2CNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139546-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139546-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-20110207748-A1 | Tri-Aryl/Heteroaromatic Cannabinoids and Use Thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2011-08-25 | — | — | US | disclosed |
| US-20110207748-A1 | Tri-Aryl/Heteroaromatic Cannabinoids and Use Thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2011-08-25 | — | — | US | disclosed |
| US-7888365-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888365-B2 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2011-02-15 | — | — | US | disclosed |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-09-25 | — | — | US | disclosed |
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234293-A1 | Tri-aryl/heteroaromatic cannabinoids and use thereof | CNR1, CNR2, OPRM1 | CNR2 2/4885CNR1 1/4885ALDH1A1 1887/4885 |
| US-20110207748-A1 | Tri-Aryl/Heteroaromatic Cannabinoids and Use Thereof | CNR1, CNR2, OPRM1 | CNR2 2/4885CNR1 1/4885ALDH1A1 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.